UW-CTRI Milwaukee Research site
Milwaukee, Wisconsin, 53233, United States
NCT Number: NCT00296647
The information gathered in this study may help to develop more effective ways to help people quit smoking and stay quit in the future.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Milwaukee, Wisconsin, 53233, United States
Randomized clinical trials may not accurately reflect the public health benefit of tobacco dependence pharmacotherapies when used in real-world clinical settings due to differences in patient selection, motivation, and adherence. To have a positive public health impact, a treatment must be accessible and acceptable to a broad range of smokers and effective under normal use conditions. The proposed project will assess primary care patients willingness to use cessation treatment and will determine the relative effectiveness of five cessation pharmacotherapies. This research builds on a primary care clinic-based recruitment strategy that was highly successful in a previous study. In the proposed research, 1320 primary care patients presenting for a regular outpatient visit will be recruited by medical assistants to participate in a free smoking cessation program and will be randomly assigned to one of five active pharmacotherapies: patch, lozenge, bupropion, patch+lozenge, and bupropion+lozenge (n = 264/condition). Interested participants who pass medical screening will pick up their medications at clinic pharmacies and will receive proactive telephone counseling from the Wisconsin Tobacco Quit Line. Assessment will be limited to preserve the generalizability of the findings, but select individual differences will be assessed pre-quit to validate algorithms (from Project 1: Efficacy) designed to optimize pharmacotherapy selection for smokers based on gender, level of dependence, and other factors. Smoking behavior will be assessed at six months and one year post-quit so that abstinence rates across pharmacotherapy conditions can be compared. The cost of incorporating tobacco dependence treatment into primary care will also be estimated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Decreasing dosages from 21 to 7 mg over 12 week period
4 mg nicotine lozenge: dosage according to package directions for 16 weeks
dosage according to prescription directions: 12 weeks
dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
Time frame: 6 months
Primary postquit outcomes was 7-day point prevalence abstinence (0, abstinent; 1, smoking) at 6 months (based on the week 24 interview)
University of Wisconsin, Madison
Other
Tobacco Dependence: Treatment and Outcomes; Pharmacotherapies: Effectiveness in Primary Care
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04832659
Chemically-Induced Disorders, Mental Disorders
Cleveland, Ohio, United States
View Trial DetailsNCT03496077
Behavior, Chemically-Induced Disorders
Farmington, Connecticut, United States
View Trial DetailsNCT05829824
Behavior, Cancer
San Francisco, California, United States
View Trial DetailsNCT06545669
Chemically-Induced Disorders, Mental Disorders
Baltimore, Maryland, United States
View Trial Details